Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sama K Carley"'
Publikováno v:
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 863-866 (2021)
Externí odkaz:
https://doaj.org/article/3842797262984da9beb6cb8e822a4330
Publikováno v:
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 863-866 (2021)
International Journal of Women's Dermatology
International Journal of Women's Dermatology
Publikováno v:
Cutis. 110
Publikováno v:
Australasian Journal of Dermatology. 63
Publikováno v:
International journal of dermatologyReferences. 61(2)
Although most cases of extramammary Paget's disease (EMPD) are localized to the intraepidermal, the extensive subclinical extension can lead to high rates of marginal recurrence with wide local excisions and topically destructive treatments. Recurren
Publikováno v:
International Journal of Dermatology. 59
Publikováno v:
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 46(1)
Background Dermal necrosis is a rare yet serious risk associated with cosmetic filler injections, and although current consensus recommends the use of hyaluronidase injections in cases of hyaluronic acid filler, the efficacy of topical nitroglycerin
Publikováno v:
Dermatology online journal. 25(3)
The treatment of cutaneous squamous cell carcinoma in situ by Mohs micrographic surgery is currently deemed as appropriate by the Mohs Appropriate Use Criteria. However, squamous cell carcinoma in situ is a very superficial, indolent, low-risk tumor
Publikováno v:
Carley, Sama K; Dixon, Anthony; Zachary, Christopher B; & Steinman, Howard K. (2019). Revised Mohs surgery care guidelines for squamous cell carcinoma in-situ are overdue. Dermatology Online Journal, 25(3). Retrieved from: http://www.escholarship.org/uc/item/5pv2370t
The treatment of cutaneous squamous cell carcinoma in situ by Mohs micrographic surgery is currently deemed as appropriate by the Mohs Appropriate Use Criteria. However, squamous cell carcinoma in situ is a very superficial, indolent, low-risk tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c71ebfdf141e3f9f00e72f95bddd828
http://www.escholarship.org/uc/item/5pv2370t
http://www.escholarship.org/uc/item/5pv2370t
Autor:
Kenneth G. Linden, Christina N. Kraus, Jessica Shiu, Rebecca Nguyen, Ashley N. Elsensohn, Larisa M. Lehmer, Franchesca Choi, Sama K Carley
Publikováno v:
Journal of the American Academy of Dermatology. 82(2)
Background Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs). Objective To analyze the evidence of PD-1 and PD-L1